SomnoMed Limited (ASX:SOM), a provider of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea, has announced that Chair Guy Russo will retire from the Board at the company's Annual General Meeting on 23 November 2026 and will not stand for re-election, with current Non-Executive Director Andrew Price selected to succeed him as Chair.

Key Points

  • Guy Russo will retire from the SomnoMed Board at the AGM on 23 November 2026 and will not stand for re-election.
  • Non-Executive Director Andrew Price has been selected by the Board to succeed Russo as Chair.
  • Mr Russo has served as Chair of SomnoMed since August 2020.
  • Mr Price joined the SomnoMed Board in January 2025 following a 25-year career at Resmed.
  • SomnoMed has commenced a search for an additional non-executive director with appropriate industry expertise.

Guy Russo's Retirement from the Chair Role

Guy Russo has served as Chair of SomnoMed since August 2020. According to the filing, the Board thanked Mr Russo for his leadership and commitment during his tenure. Mr Russo said it had been a privilege to serve as Chair over the past six years, expressing gratitude to fellow directors, the management team, and the company's people around the world. He noted confidence in his successor and indicated he looks forward to a seamless handover.

Andrew Price's Appointment as Incoming Chair

Andrew Price joined the SomnoMed Board in January 2025 following a 25-year career at Resmed, where his senior executive roles spanned global product development, project management, and business development. As Chief Supply Chain Officer at Resmed, he led end-to-end supply chain operations including supplier management, manufacturing, logistics, distribution, quality assurance, and regulatory affairs. Mr Price holds an Industrial Design degree from the University of Technology Sydney, has completed INSEAD's Advanced Management Program in Singapore, and is a Graduate of the Australian Institute of Company Directors.

Additional Board Appointment Search Under Way

In addition to the chair transition, SomnoMed disclosed it has commenced a search for an additional non-executive director to be appointed to the Board, targeting appropriate industry expertise. The filing states that Mr Price commented he is honoured to have been selected as SomnoMed's next Chair. He also acknowledged the opportunity to work with Chief Executive Officer Karen Borg, the leadership team, and the Board. The filing was approved by the Board of SomnoMed Limited.